Recent Updates
Recently added Catalysts

Lite Strategy, Inc.

LITSFDA catalysts, PDUFA dates & pipeline intelligence
$0.84
▲ +0.03 · +3.61%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full LITS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.6952W HIGH $1.99
Volume
134.37 K
Value Traded
113.30 K
Short % Float
0.4%
Days to Cover
1.0
-7.78%Week
-29.72%1 Month
-11.35%3 Month
-23.97%6 Month
-99.91%5 Year
-100%All Time

Cash Data

Unlock LITS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
25.43 M
EPS (TTM)
-1.72
P/E Ratio
-
Ent. Value
21.15 M
Total Shares
30.41 M
Float Shares
29.40 M
Insiders
1.62%
Institutions
16.93%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every LITS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

LITS Catalyst Timeline

Dated clinical, regulatory and corporate events for Lite Strategy, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Lite Strategy, Inc.

263Total events
4Upcoming
60Tier-1 (high impact)
2005 to 2027Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
TBD
T3Preclinical PoC
Subscribe to view catalyst details
zandelisib

Event history 50

●Quarterly UpdateCorporate
Lite Strategy reports fiscal 2027 first quarter results for period ended September 30, 2026
●Quarterly UpdateCorporate
Reported financial results for fiscal year ended June 30, 2026
●R&D DayPresentation
Lite Strategy to present at 28th Annual H.C. Wainwright Global Investment Conference
●Other Regulator MilestoneEx-US Regulatory
SEC proposed Regulation Crypto Assets, open for public comment
◆Oral PresentationPresentation
Lite Strategy to attend panel at Litecoin Foundation Summit in Amsterdam
▲Other Regulator MilestoneEx-US Regulatory
SEC issued Digital Asset Interpretation identifying LTC as a digital commodity
▲Partnership / LicenseCorporate
Led a $1.0 million strategic investment in LitVM
◆Topline ReadoutvoruciclibClinical Data
Stage 2 topline readout at RP2D
R/R AMLsource ↗
▲ATM ProgramCorporate
Board authorizes $25M share repurchase program
●Corporate ApprovalCorporate
$25.0 million share repurchase program approved
Unlock the full LITS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How LITS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all LITS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 97%
Micro Cap
(rank 701 of 723)
Percentile Rank
Showing 2 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
PWT-143 Small MoleculesCompletedNCT02521389MalignanciesPhase 1 COMPLETED 35Feb 24, 2017
ME-344 Small MoleculesCompletedNCT01544322Solid TumorsPhase 1 COMPLETED 24Aug 1, 2014
Unlock the LITS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every LITS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
voruciclib acute myeloid leukemia and B-cell malignanciesPhase 12023-12-11favorable safety profile; no observed overlapping toxicities; meaningful anti-tumor activity; 40 patients enrolled; median age 75 years (range 63-80)Read Moreinability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the paRead More
Scroll for more · summaries link to the source press release
Unlock every LITS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock LITS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Flynn James PDirectorBuy 27,450 152,450 held$0.79 11/17/2026
Unlock the full LITS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in LITS for Q3 2026.
Unlock every fund holding LITS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in LITS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see LITS ownership
Insider and institutional ownership, quarter by quarter.

LITS Short Interest

Shares sold short, counted twice a month.

0.4%
Short % of Float
of tradable shares sold short
118.9K
Shares Sold Short
+9.5% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
197.9K
Avg Daily Volume
the average used for days to cover
Unlock LITS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock LITS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live LITS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock LITS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How LITS ranks across every disease it competes in

Competitive Position is a premium feature
See how LITS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

LITS News

LITS
Nov 10, 2026
LITSGeneral

Lite Strategy Reports Fiscal 2027 First Quarter Financial Results

Lite Strategy, Inc. reported strong financial results for Q1 2027, achieving a net income of $16.0 million, primarily due to a 60% appreciation in Litecoin. The company reduced operational cash usage by 52% and maintained a debt-free balance sheet while repurchasing 2.2 million shares. Management aims to enhance LTC backing for shares and expand its treasury operations.

Read more →
LITS
Oct 13, 2026
LITSGeneral

Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive

Lite Strategy, Inc. has launched 'Proof of Time', an archive celebrating 15 years of Litecoin's history and its impact on the crypto ecosystem. The project highlights the network's reliability, with over a million transactions weekly and a strong holder base. The company aims to document the human stories behind Litecoin's success as it continues to evolve.

Read more →
LITS
Sep 29, 2026
LITSGeneral

Lite Strategy Reports Fiscal Year 2026 Financial Results

Lite Strategy, Inc. reported its fiscal year 2026 financial results, marking the first year of its Litecoin treasury strategy. The company acquired over 900,000 LTC and initiated a covered call program to enhance shareholder value. Despite regulatory uncertainties, management remains optimistic about LTC's growth potential and plans to expand its treasury operations. The company also retains pharmaceutical assets for potential out-licensing.

Read more →
LITS
Sep 10, 2026
LITSConferences/Events

Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York

Lite Strategy, Inc. will present at the 28th Annual H.C. Wainwright Global Investment Conference in New York from September 14-16, 2026. The company, known for adopting Litecoin as its primary treasury reserve asset, aims to engage with institutional investors to discuss its capital markets strategy. CEO Jay File emphasized the importance of the conference for articulating their vision and building momentum.

Read more →
LITS
Jul 30, 2026
LITSGeneral

Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share

Lite Strategy, Inc. has repurchased approximately 4.9 million shares, representing 13% of its outstanding shares, since initiating its Share Repurchase Program in December 2025. The buyback was funded through treasury operations and has effectively increased the Litecoin backing per share while narrowing the discount to net asset value. The company plans to continue this program as long as it remains beneficial for stockholders.

Read more →
LITS
Jun 19, 2026
LITSConferences/Events
▲ +8%on this news

Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

Lite Strategy, Inc. will participate in the Litecoin Foundation Summit on June 22-23, 2026, in Amsterdam. This marks the first appearance of a NASDAQ-listed digital asset treasury company at the event, showcasing the institutional adoption of Litecoin. The panel will feature key figures from Lite Strategy and the Litecoin Foundation, discussing the future of Litecoin as a reserve asset.

Read more →
LITS
Jun 18, 2026
LITSGeneral
▼ -9.9%on this newsshared move

Lite Strategy Leads Strategic Investment in LitVM

Lite Strategy, Inc. has closed a $1.0 million strategic investment in ZK Innovations Inc., the developer of LitVM, a zero-knowledge Layer 2 platform for Litecoin. This investment aims to enhance Litecoin's functionality, enabling decentralized finance and smart contracts. Lite Strategy's CEO emphasized the importance of building infrastructure to create shareholder value. The investment aligns with the upcoming launch of LitVM's mainnet, which will introduce new capabilities to the Litecoin ecosystem.

Read more →
LITS
May 13, 2026
LITSGeneral
▼ -5.6%on this news

Lite Strategy Reports Fiscal 2026 Third Quarter Results

Lite Strategy, Inc. reported its fiscal 2026 third quarter results, highlighting successful treasury management and a robust covered call option program. The company generated $0.7 million in net proceeds and repurchased over 1.6 million shares. CEO Jay File emphasized the focus on generating yield from Litecoin holdings while enhancing shareholder value. The SEC's recent guidance classifying Litecoin as a digital commodity is seen as a positive development for the company and the broader Litecoin ecosystem.

Read more →
LITS
Feb 17, 2026
LITSGeneral

Lite Strategy Reports Fiscal 2026 Second Quarter Results

Lite Strategy, Inc. reported its fiscal 2026 second quarter results, highlighting a strategic shift to actively manage its Litecoin (LTC) holdings. The company generated significant revenue through covered call options and initiated a $25 million stock repurchase program. Management aims to differentiate itself from passive digital asset vehicles by enhancing shareholder value and supporting the Litecoin ecosystem.

Read more →
LITS
Nov 17, 2025
LITSGeneral
▼ -5.9%on this news

Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

Lite Strategy, Inc. (LITS) reported strong first-quarter results for fiscal year 2026, highlighting its $100 million Litecoin treasury strategy and its status as the first U.S. public company to adopt Litecoin as a primary reserve asset. The company also announced a strategic partnership with GSR to guide its digital asset treasury strategy. Despite its successes, LITS faces risks related to market fluctuations and regulatory challenges.

Read more →
LITS
Oct 29, 2025
LITSGeneral
▲ +7.8%on this news

Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

Lite Strategy, Inc. has announced a $25 million share repurchase program to enhance stockholder value. The program allows for shares to be bought back in the open market or through negotiated transactions. The company aims to optimize its Litecoin treasury and adapt to market conditions, although the timing and number of shares purchased will depend on market dynamics.

Read more →
LITS
Oct 29, 2025
LITSGeneral
▲ +7.8%on this news

Lite Strategy Announces $25M Share Repurchase Program, Signalling Shift From Initial Litecoin Accumulation to Active Capital Market Operations LITS Board of Directors Reaffirms Commitment to Driving Long-Term Stockholder Value

Lite Strategy, Inc. (LITS) announced a $25 million share repurchase program, indicating a strategic shift from accumulating Litecoin to engaging in active capital market operations. The Board of Directors aims to enhance stockholder value through this initiative, which allows for the repurchase of shares based on market conditions. The company may also implement a Rule 10b5-1 trading plan to facilitate these purchases. However, potential risks include challenges in executing the repurchase effectively and fluctuations in the value of Litecoin impacting operations.

Read more →
LITS
Oct 16, 2025
LITSGeneral

Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026

Lite Strategy, Inc. celebrates the 14th anniversary of Litecoin, highlighting its reliability and institutional interest. The company positions itself as a pioneer in providing institutional access to Litecoin through public markets. Despite challenges like the ongoing government shutdown, Lite Strategy aims to attract investors seeking exposure to this digital asset.

Read more →
LITS
Sep 10, 2025
LITSGeneral

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker LITS' Lite Strategy Rebrand Aligns with Company's LTC Digital Asset Treasury Strategy Advised by GSR Ventures

Lite Strategy, Inc., formerly MEI Pharma, has rebranded to highlight its focus on adopting Litecoin as its primary reserve asset. The company has secured over $100 million in Litecoin and aims to pioneer digital asset treasury management. Alongside the rebranding, Lite Strategy continues to evaluate its drug development pipeline, suggesting a blend of innovative digital strategies with traditional biotechnology initiatives. The partnership with LTC creator Charlie Lee and GSR Ventures is expected to strengthen its market approach.

Read more →
LITS
Aug 4, 2025
LITSGeneral

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

MEI Pharma, Inc. announced its acquisition of 929,548 Litecoin tokens as part of a $100 million institutional treasury strategy, making it the first U.S.-listed public company to adopt Litecoin as a reserve asset. This initiative is in partnership with GSR and guided by Litecoin founder Charlie Lee, emphasizing the scalability and reliability of Litecoin for treasury purposes. In addition to this strategic step, MEI Pharma is also planning further development in its drug candidate pipeline.

Read more →
LITS
Jul 18, 2025
LITSGeneral

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

MEI Pharma recently announced a $100 million private placement aimed at initiating a Litecoin treasury strategy, making it the first publicly traded company to adopt Litecoin as a treasury reserve asset. The transaction will appoint Litecoin’s founder, Charlie Lee, to its Board of Directors and engage GSR as a digital asset advisor. This strategy reflects a significant shift toward integrating cryptocurrency into corporate financial practices, with expectations for broader adoption in traditional capital markets. The company aims to bolster its cash management framework through the holding of LTC.

Read more →
LITS
May 13, 2025
LITSGeneral

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing

MEI Pharma reported its third quarter results for fiscal year 2025, indicating a cash position of $20.5 million and no debt. The company is actively evaluating strategic alternatives, including potential out-licensing and M&A opportunities, with the aim of maximizing asset value for shareholders. However, there is uncertainty surrounding the success of these strategies and a reduction in workforce is being implemented, which may affect operational capabilities.

Read more →
LITS
Feb 12, 2025
LITSGeneral

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing

MEI Pharma reported its financial results for the second quarter of fiscal year 2025, revealing a cash position of $23.7 million. The company is actively exploring strategic alternatives, including potential mergers or out-licensing opportunities, to enhance the value of its assets. However, the evaluation process carries risks, and there is no assurance that it will result in successful transactions. Furthermore, MEI Pharma has initiated workforce reductions as part of its cash preservation efforts amid continued operational and financial challenges.

Read more →
LITS
Nov 12, 2024
LITSGeneral

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position Reaffirms Continuation of Evaluation of Strategic Alternatives

MEI Pharma reported its first-quarter results for fiscal year 2025, indicating a cash position of $26.9 million without any debt. The company confirmed its ongoing evaluation of strategic alternatives to maximize asset value, involving potential out-licensing and merger opportunities. However, they have commenced cash preservation efforts including staff reductions that will occur in stages. The press release highlighted uncertainties about the success of these strategies and warned stakeholders of various risks that may affect potential agreements.

Read more →
LITS
Sep 19, 2024
LITSGeneral

MEI Pharma Reports Fiscal Year End 2024 Cash Position Confirms Continuation of Evaluation of Strategic Alternatives

MEI Pharma, Inc. has reported its financial results for the fiscal year ending June 30, 2024. The company is evaluating strategic alternatives to enhance the value of its assets for shareholders, including potential mergers and acquisitions. To conserve its cash, MEI has initiated workforce reductions and stopped the clinical development of its drug voruciclib. As of the end of the fiscal year, the company holds $38.3 million in cash and equivalents, with rising concerns regarding the success of its strategic evaluations.

Read more →

About Lite Strategy, Inc.

San Diego, CA 5 employees litestrategy.com
Headquarters9920 PACIFIC HEIGHTS BLVD, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE
Trade the next LITS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime